Teriparatide — EU research guide.
Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34) that, unlike constantly elevated PTH, builds new bone when given as a once-daily pulse — the original bone-anabolic peptide that abaloparatide was later designed to improve on.
What is Teriparatide?
Teriparatide reproduces the first 34 amino acids of human PTH. Given as a single daily injection, this intermittent dosing pattern paradoxically stimulates osteoblasts to build new bone, rather than triggering the bone breakdown seen with chronically elevated PTH.
What does the research show?
Approved for severe osteoporosis since 2002 (US) and shortly after in the EU, teriparatide has extensive trial data showing reduced vertebral and non-vertebral fracture risk. It directly informed the design of abaloparatide, a related analogue with a more bone-selective receptor-binding profile and fewer off-target effects.
EU legal status
EMA-approved prescription medicine (Forteo, and generic Terrosa/Movymia) for osteoporosis, with a maximum lifetime treatment duration of 24 months due to a rodent osteosarcoma signal at high, prolonged doses.
Molecular information
Pharmacokinetics
Bone-pathway compounds across EU suppliers
COA-verified EU vendors · Updated monthly